- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02717429
Cognitive and Emotion Regulation Training in MS (CERT-MS)
April 13, 2018 updated by: Ruchika Prakash, Ohio State University
Cognitive and Emotion Regulation Training in Multiple Sclerosis
The investigators propose to conduct a randomized feasibility study of mindfulness meditation training (MMT) relative to an active cognitive training control group and waitlist control group in improving emotional regulation in individuals with MS.
Individuals will complete pre- and post-assessments of emotional functioning through a week of daily diary entries, as well as self-report measures and a behavioral paradigm.
Additionally, all participants will complete an evaluation of neuropsychological functioning, before and after intervention.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
Epidemiological data provides evidence for the manifold increase in rates of depression and anxiety in individuals diagnosed with multiple sclerosis, relative to the general population.
Such impaired affective processes, including deficits in emotion regulation have been linked to greater cognitive deficits, a lower quality of life, and greater disease progression in this population.
Despite evidence of the deleterious impact of affective functioning on prevalence rates of mood and anxiety disorders; on poor cognitive functioning; and reduced quality of life, much of the targeted intervention research in MS has not directly tested the feasibility, and subsequent efficacy of a psychosocial intervention in improving affective regulation in this population.
Thus, the investigators propose to conduct a randomized feasibility study of mindfulness training relative to an active cognitive training control group and waitlist control group in improving emotional regulation in individuals with MS.
All individuals that contact the Clinical Neuroscience Laboratory (CNLab) with interest in this study will undergo a phone screening assessing inclusion/exclusion criteria.
Those participants meeting I/E criteria will be invited for an online daily diaries portion of the study examining daily engagement in worry and rumination.
After completing the week-long daily diary portion of the study, the participant will attend 1-2 in-person pre-assessment sessions, which will also be completed at the completion of the four week intervention.
The pre-assessment will involve a thorough assessment of emotion regulation skills, both through self-report questionnaires and behavioral paradigms, and cognitive functioning.
Following the assessment sessions, which will be conducted by blind assessors, participants will be randomized to the three groups.
The 4-week mindfulness program will be closely modeled after the protocol developed by Dr. Jon Kabat-Zinn, where investigators will have the participants attend once-per-week sessions for 2 hours and complete around 40 minutes a day of homework assignments.
The four weeks of mindfulness involve the practice of concentrative attention, where different objects are used as the focus of practices.
For example, for the first two weeks, the investigators use breath as an anchor for the mind.
With repeated practices, the objects of sensations, emotions, and thought processes are introduced.
The classes are a mixture of experiential practices, discussions surrounding the experiences, and didactics on mindfulness.
The control group, which will be used to compare the effects of mindfulness training on emotional and cognitive functioning of MS patients, will comprise of a cognitive training group, which will provide an attentional-training based approach.
In this group, our focus will be to provide the individuals with cognitive training tasks to complete that have been shown to improve attentional ability.
Homework will be reading and practicing using the cognitive video game exercises for the same duration, around 40 minutes daily, as the mindfulness group.
Following the four weeks of the intervention, the questionnaires, week-long daily diaries, and behavioral tests from the pretest will be repeated a second time to obtain post-test data for comparison.
Study Type
Interventional
Enrollment (Actual)
62
Phase
- Not Applicable
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Ohio
-
Columbus, Ohio, United States, 43210
- Department of Psychology, The Ohio State University
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
30 years to 59 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- 30-59 years of age
- Score higher than or equal to 23 on the Mini Mental Status Examination (MMSE)
- Corrected (near and far) visual acuity of 20/40 or better
- No previous experience with mindfulness or continuous meditation practice
- Absence of other co-morbid neurological disorders
- Relapse free for the last 30 days
- No use of corticosteroids for the last 30 days
- Clinically definite diagnosis of MS
- Ability to use a computer and connect the internet from their home
- Generation of at least two worries and two ruminations during the daily diary portion of the study for the pre-assessment session
Exclusion Criteria:
- Below 30 years of age or above 59 years of age
- Score lower than 23 on the MMSE
- Corrected (near or far) visual acuity of 20/40 or greater
- Previous experience or participation in a mindfulness program
Presence of co-morbid neurological disorders such as:
- Alzheimers
- Parkinson's disease
- Dementia
- Presence of a relapse within the last 30 days
- Use of corticosteroids within the last 30 days
- Clinically isolated syndrome suggestive of MS
- No ability to use a computer and/or a lack of internet connection from their home
- No self-generated worries and ruminations in the week-long daily diary portion of the study at pre-assessment
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Mindfulness Meditation Training (MMT)
Participants will attend four weekly group mindfulness meditation sessions of a 2-hour duration.
The classes are a mixture of experiential practices, discussions surrounding the experiences, and didactics on mindfulness.
In addition to the time spent in session, participants will be asked to complete 40 minutes of daily homework, which includes further practice of in-session meditative exercises and brief readings.
|
The mindfulness meditation-training program is closely modeled after the 8-week mindfulness based stress reduction protocol developed by Dr. Jon Kabat-Zinn.
The briefer four weeks of MMT involve the practice of concentrative attention, where different objects are used as the focus of meditative practices.
For example, for the first two weeks, the investigators use breath as an anchor for attention.
With repeated practices, the objects of sensations, emotions, and thought processes are introduced.
|
|
Active Comparator: Computerized Cognitive Training
The active control group will be in the form of a cognitive training course where the participants will meet for the same amount of time as the MMT group.
Homework will be reading and engaging in cognitive video game exercises for the same duration, around 40 minutes daily, as the MMT group.
|
The control group, which will be used to compare the effects of mindfulness training on emotional and cognitive functioning of MS patients, will comprise of a cognitive training group, which will provide an attentional-training based approach.
In this group, the focus will be to provide the individuals with cognitive training tasks to complete that have been shown to improve attentional ability.
The investigators will also discuss relevant MS-related material on cognitive deficits during these courses.
|
|
No Intervention: Wait-List Control Group
This group will be used to compare the effects of the two active comparison groups and will not receive any intervention for the four week period.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Change in Reported Engagement After Worry and Rumination Inductions
Time Frame: Baseline and 4 weeks
|
Participants will engage in worry and rumination inductions during both the pre- and post-intervention sessions.
These worries and ruminations will be sampled from the daily diaries participants will fill out 7-days before the pre- and post-intervention sessions.
Investigators will be examining the change in emotion and strategy implementation over the course of the worry and rumination inductions.
Specifically, investigators will examine the change in reported negative and positive emotion related to the worry and rumination inductions from pre- to post-intervention.
Further, investigators will examine the induction-related change in strategy implementation, specifically worry and rumination, over the 4-weeks of intervention.
|
Baseline and 4 weeks
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Cognitive Performance on Brief Repeatable Battery (BRB)
Time Frame: Baseline and 4 weeks
|
Participants will perform the entire Brief Repeatable Battery before and after the intervention.
Using the categorization developed by Sepulcher (2013), the 5 tests of the BRB will be analyzed using four cognitive domains: attention and executive functioning, verbal memory, visual memory, and word fluency.
Based on the computerized cognitive training protocol employed in the current study, investigators hypothesize changes in attention and executive functioning along with visual memory in participants in the cognitive training group, followed by participants in the MMT group compared with the wait-list control participants.
|
Baseline and 4 weeks
|
|
Heart Rate Variability (HRV)
Time Frame: Baseline and 4 weeks
|
HRV data will be collected during worry and rumination inductions, as participants regulate their emotions, and at rest.
|
Baseline and 4 weeks
|
|
Daily Emotion Regulation Diary
Time Frame: Baseline and 4 weeks
|
Participants will be asked to fill out worry and ruminations using a diary-based methodology a week before the pre-intervention behavioral session and one week after the post-intervention sessions.
Changes in average self-reported worry and rumination intensity, emotion regulation strategy use, and successful emotion regulation strategy implementation will be examined as a function of the intervention.
|
Baseline and 4 weeks
|
|
Improvements on a Self-Report Measure of Emotion Dysregulation
Time Frame: Baseline and 4 weeks
|
Emotion Dysregulation will be assessed using the Difficulties in Emotion Regulation Scale (DERS).
Changes on the total score and sub-facets of DERS will be examined as a function of the intervention.
|
Baseline and 4 weeks
|
|
Improvements on a Self-Report Measure of Depression
Time Frame: Baseline and 4 weeks
|
Participants will be administered Beck Depression Inventory before and after the intervention.
Change on this measure will be examined to assess the impact of the interventions on symptoms of depression.
|
Baseline and 4 weeks
|
|
Improvements on a Self-Report Measures of Anxiety
Time Frame: Baseline and 4 weeks
|
Participants will be administered Penn State Worry Questionnaire before and after the intervention.
Change on this measure will be examined to assess the impact of the interventions on symptoms of worry.
|
Baseline and 4 weeks
|
|
Improvements on a Self-Report Measure of Perceived Stress
Time Frame: Baseline and 4 weeks
|
Participants will be administered the Perceived Stress Scale before and after the intervention.
Changes in these measures will be examined as a function of the intervention.
|
Baseline and 4 weeks
|
|
Improvements on a Self-Report Measure of Quality of Life
Time Frame: Baseline and 4 weeks
|
Participants will be administered the Satisfaction with Life Scale before and after the intervention.
Change in scores of this measure will be examined to assess changes in quality of life as a function of the interventions.
|
Baseline and 4 weeks
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Investigators
- Principal Investigator: Ruchika S Prakash, PhD, Ohio State University
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
General Publications
- Duraney EJ, Fisher ME, Manglani HR, Andridge RR, Nicholas JA, Prakash RS. Impact of mindfulness training on emotion regulation in multiple sclerosis: Secondary analysis of a pilot randomized controlled trial. Rehabil Psychol. 2022 Nov;67(4):449-460. doi: 10.1037/rep0000456. Epub 2022 Jul 28.
- Schirda B, Duraney E, Lee HK, Manglani HR, Andridge RR, Plate A, Nicholas JA, Prakash RS. Mindfulness training for emotion dysregulation in multiple sclerosis: A pilot randomized controlled trial. Rehabil Psychol. 2020 Aug;65(3):206-218. doi: 10.1037/rep0000324. Epub 2020 May 7.
- Manglani HR, Samimy S, Schirda B, Nicholas JA, Prakash RS. Effects of 4-week mindfulness training versus adaptive cognitive training on processing speed and working memory in multiple sclerosis. Neuropsychology. 2020 Jul;34(5):591-604. doi: 10.1037/neu0000633. Epub 2020 Apr 30.
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2015
Primary Completion (Actual)
May 14, 2017
Study Completion (Actual)
May 14, 2017
Study Registration Dates
First Submitted
October 21, 2015
First Submitted That Met QC Criteria
March 17, 2016
First Posted (Estimate)
March 23, 2016
Study Record Updates
Last Update Posted (Actual)
April 17, 2018
Last Update Submitted That Met QC Criteria
April 13, 2018
Last Verified
April 1, 2018
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 2014H0212
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
NO
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Multiple Sclerosis
-
University Hospital, Basel, SwitzerlandSwiss National Science FoundationRecruitingMultiple Sclerosis (MS) | Relapsing-remitting Multiple Sclerosis (RRMS) | Secondary-progressive Multiple Sclerosis (SPMS) | Primary Progressive Multiple Sclerosis (PPMS)Switzerland
-
University of California, Los AngelesUnknownRelapsing-remitting Multiple Sclerosis | Secondary-progressive Multiple Sclerosis | Primary-progressive Multiple SclerosisUnited States
-
BiogenCompletedMultiple Sclerosis | Relapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Multiple Sclerosis, Primary Progressive | Multiple Sclerosis, Remittent ProgressiveJapan
-
Cabaletta BioNot yet recruitingProgressive Multiple Sclerosis | Multiple Sclerosis | Multiple Sclerosis (Relapsing Remitting) | Relapsing Multiple Sclerosis (RMS) | Progressive Multiple Sclerosis (PMS) | Multiple Sclerosis (MS) - Relapsing-remitting | Multiple Sclerosis - Relapsing Remitting
-
Rigshospitalet, DenmarkOdense University Hospital; Aarhus University Hospital; Hvidovre University Hospital and other collaboratorsActive, not recruitingRelapsing Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisDenmark
-
The Cleveland ClinicUniversity Hospitals Cleveland Medical CenterCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple Sclerosis | Progressive Relapsing Multiple SclerosisUnited States
-
Icahn School of Medicine at Mount SinaiColumbia University; New York Stem Cell Foundation Research InstituteCompletedClinically Isolated Syndrome | Relapsing-Remitting Multiple Sclerosis | Primary Progressive Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
-
Novartis PharmaceuticalsCompletedRelapsing-remitting Multiple Sclerosis | Active Secondary Progressive Multiple SclerosisJapan
-
Banc de Sang i TeixitsVall d'Hebron Research Institute (VHIR)CompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisSpain
-
BiogenElan PharmaceuticalsCompletedRelapsing-Remitting Multiple Sclerosis | Secondary Progressive Multiple SclerosisUnited States
Clinical Trials on Mindfulness Meditation
-
Oregon Health and Science UniversityCompleted
-
University Hospital, AngersWithdrawnLateral Sclerosis Amyotrophy | Mindfulness Meditation
-
University of Illinois at Urbana-ChampaignNorthwestern University Feinberg School of Medicine; Southern Illinois University and other collaboratorsNot yet recruitingPain, Postoperative | Depression, Unipolar
-
Equa HealthNational Institute of Mental Health (NIMH); Worcester Polytechnic InstituteRecruitingPsychological Distress | Mindfulness Skills | Usability SatisfactionUnited States
-
Barbara L. Fredrickson, PhDNational Center for Complementary and Integrative Health (NCCIH)Completed
-
Universiti Tunku Abdul RahmanRecruiting
-
Icahn School of Medicine at Mount SinaiTerminatedPain, Postoperative | Spine Surgery | MeditationUnited States
-
York UniversityCompletedChronic Pain | Depression, AnxietyCanada
-
Jordan University of Science and TechnologyCompletedChronic Kidney Diseases | Hemodialysis ComplicationJordan
-
Kaiser PermanenteCompletedDepression | Anxiety | Advanced CancerUnited States